Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1 ^USD	+1.20%		-9.09%	-9.91%

Apr. 15	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
Apr. 15	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

January 25, 2024 at 08:05 am EST

Organovo Holdings, Inc. announced the presentation of preclinical data related to the company's FXR314 development program in its proprietary 3D human tissue models of Crohn's disease and ulcerative colitis at the Crohn's and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada. FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD. The presentation highlights preclinical data characterizing the activity of FXR314 in 3D models of human Crohn's disease and Ulcerative colitis.

FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all Crohn's disease donors. The company plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 2024, with targeted completion in 2025. The drug?s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that.

Latest news about Organovo Holdings, Inc.

Organovo's fatty liver disease drug meets main goal in mid-stage study	Apr. 15	RE
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 15	CI
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	Jan. 25	CI
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	Dec. 06	CI
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	Nov. 08	CI
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23	CI
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-14	CI
Organovo Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-07-13	CI
North American Morning Briefing : Optimism Set to -2-	23-07-13	DJ
North American Morning Briefing : Fed Hawks Hit -2-	23-07-06	DJ
North American Morning Briefing : Claims Data, GDP -2-	23-06-29	DJ
North American Morning Briefing : Stock Futures -2-	23-06-22	DJ
North American Morning Briefing : Traders Digest -2-	23-06-15	DJ
North American Morning Briefing : Nasdaq Futures -2-	23-06-08	DJ
North American Morning Briefing : Stock Futures -3-	23-02-10	DJ
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates	22-11-15	CI
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-10	CI
Organovo Holdings to Proceed With Target Discovery, Validation for Crohn's Disease After Achieving 3D Tissue Model	22-05-17	MT
Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease	22-05-17	CI

Chart Organovo Holdings, Inc.

Duration

Period

More charts

Company Profile

Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
ORGANOVO HOLDINGS, INC.	-9.91%	11.39M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research